CORDIS
EU research results

CORDIS

English EN
Exploiting MELanoma disease comPLEXity to address European research training needs in translational cancer systems biology and cancer systems medicine

Exploiting MELanoma disease comPLEXity to address European research training needs in translational cancer systems biology and cancer systems medicine

Objective

Novel treatment options and associated personalised, patient-tailored therapies need to be explored and developed for highly heterogeneous and chemotherapy resistant cancers, such as malignant melanoma. This can only be achieved by industry-academia collaborations in newly emerging, innovative research disciplines such as translational cancer systems biology and systems medicine. These disciplines and the associated European training needs provide the foundation for the MEL-PLEX ETN. MEL-PLEX aims to understand the network-level and multi-scale regulation of disease-relevant signalling in melanoma through a combination of quantitative biomedical and computational research approaches that go significantly beyond the current state-of-the-art. Coordinated by the RCSI Centre for Systems Medicine, MEL-PLEX will train 15 early stage researchers through a highly interdisciplinary and intersectoral research training programme. MEL-PLEX comprises 11 beneficiaries and 7 partner organisations from 11 countries, including European and international leaders in personalised melanoma therapy, melanoma systems biology and cancer systems medicine. MEL-PLEX aims to (i) achieve an unmatched depth of molecular and mechanistic disease understanding, (ii) will exploit this knowledge to develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iii) will provide superior and clinically relevant tools and biomarker signatures for personalising and optimising melanoma treatment. The MEL-PLEX ETN addresses current needs in academia and the private sector for researchers that have been trained in an environment that spans across biology, medicine and mathematics, that can navigate confidently between clinical, academic and private sector research environments, and that have developed an innovative and creative mindset to progress research findings towards applications.

Coordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND

Address

Saint Stephen'S Green 123
2 Dublin

Ireland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 184 496,25

Participants (11)

Sort alphabetically

Sort by EU Contribution

Expand all

TECHNISCHE UNIVERSITAET DRESDEN

Germany

EU Contribution

€ 498 432,96

UNIVERSITE DU LUXEMBOURG

Luxembourg

EU Contribution

€ 501 120

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 501 120

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

Germany

EU Contribution

€ 55 381,44

ONCOMARK LIMITED

Ireland

EU Contribution

€ 265 674,60

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

Ireland

EU Contribution

€ 265 674,60

OPTIMATA LTD

Israel

EU Contribution

€ 260 300,52

KRAEFTENS BEKAEMPELSE

Denmark

EU Contribution

€ 290 081,88

PROTATOUANS - ETAIREIA EREYNAS VIOTECHNOLOGIAS MONOPROSOPI ETAIREIA PERIORISMENIS EYTHINIS

Greece

EU Contribution

€ 242 386,92

UNIVERSITAET STUTTGART

Germany

EU Contribution

€ 477 664,92

UNIVERSITAETSKLINIKUM AACHEN

Germany

EU Contribution

€ 41 536,08

Partners (8)

Sort alphabetically

Expand all

University Berne

Merrimack

Apogenix

Novartis

A. Plaisant Srl.

Mass. General Hospital

Galderma

THE HEBREW UNIVERSITY OF JERUSALEM

Project information

Grant agreement ID: 642295

Status

Closed project

  • Start date

    1 December 2014

  • End date

    30 November 2018

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 583 870,17

  • EU contribution

    € 3 583 870,17

Coordinated by:

ROYAL COLLEGE OF SURGEONS IN IRELAND

Ireland